In the latest market close, Organon (OGN) reached $19.17, with a +0.74% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.4% for the day. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%. The pharmaceutical company's stock has dropped by 15.31% in the past month, falling short of the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the ...

Organon (OGN) ended the recent trading session at $20.47, demonstrating a +0.89% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.72%, and the technology-centric Nasdaq increased by 0.65%. Shares of the pharmaceutical company witnessed a gain of 0.35% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%. The upcoming earn ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this pharmaceutical company have returned +1%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Altho ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this pharmaceutical company have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term? Alt ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned -2.5% over the past month versus the Zacks S&P 500 composite's -3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 0.7% over this period. Now the key question is: Where could the stock be headed in the near term? Although media re ...

Organon (OGN) reported $1.61 billion in revenue for the quarter ended June 2024, representing a year-overyear decline of 0.1%. EPS of $1.12 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -1.13% over the Zacks Consensus Estimate of $1.63 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +5.66%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

Organon & Co. (NYSE:OGN) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Jennifer Halchak - Head of IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Umer Raffat - Evercore ISI Ethan Brown - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Operator Thank you for standing-by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ...

Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.97 per share when it actually produced earnings of $1.22, delivering a surprise of 25.77%. Over the last four quarters, the co ...

Organon & Co. (OGN) is scheduled to report second-quarter 2024 results on Aug 6, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of $1.22 surpassed the Zacks Consensus Estimate by 25.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 13.6%, on average. Let's check out the factors that have shaped OGN's performance prior to this announcement. Factor ...

Wall Street analysts expect Organon (OGN) to post quarterly earnings of $1.06 per share in its upcoming report, which indicates a year-over-year decline of 19.1%. Revenues are expected to be $1.63 billion, up 1.1% from the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company announces its earni ...